Lyme Disease

condition

Last mentioned: Mar 25, 2026

Timeline

2025
Regulatory Submission

Anticipated filing for FDA and EMA approval based on final trial data.
March 2024
Efficacy Milestone

Trial results indicate efficacy exceeding the 70% threshold.
August 2022
Phase 3 Launch

The VALOR trial begins enrolling thousands of participants in endemic areas.
April 2020
Partnership Formed

Pfizer and Valneva enter a collaboration agreement to develop VLA15.

Stories mentioning Lyme Disease 1

Pfizer Reports Over 70% Efficacy for Landmark Lyme Disease Vaccine Trial

Pfizer and Valneva have announced that their Lyme disease vaccine candidate, VLA15, demonstrated more than 70% efficacy in late-stage clinical trials. This breakthrough marks the first successful human vaccine development for the tick-borne illness in over two decades, addressing a critical gap in public health.

Mar 25, 2026 2 sources